Pegfilgrastim biosimilar - PharmaEssentiaAlternative Names: PEG-GCSF - PharmaEssentia
Latest Information Update: 13 Oct 2015
At a glance
- Originator PharmaEssentia Corporation
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Neutropenia
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 31 Dec 2014 Phase-I clinical trials in Neutropenia in Taiwan (Parenteral)